JP2024502371A5 - - Google Patents
Info
- Publication number
- JP2024502371A5 JP2024502371A5 JP2023541864A JP2023541864A JP2024502371A5 JP 2024502371 A5 JP2024502371 A5 JP 2024502371A5 JP 2023541864 A JP2023541864 A JP 2023541864A JP 2023541864 A JP2023541864 A JP 2023541864A JP 2024502371 A5 JP2024502371 A5 JP 2024502371A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- bispecific epitope
- cancer
- bispecific
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135812P | 2021-01-11 | 2021-01-11 | |
| US63/135,812 | 2021-01-11 | ||
| PCT/IB2022/000009 WO2022149050A2 (en) | 2021-01-11 | 2022-01-11 | Bispecific epitope binding protein comprising anti-4-1bb antibody and pd-1 protein or fragments thereof and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502371A JP2024502371A (ja) | 2024-01-18 |
| JP2024502371A5 true JP2024502371A5 (https=) | 2025-01-23 |
Family
ID=82357225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541864A Pending JP2024502371A (ja) | 2021-01-11 | 2022-01-11 | 抗－４－１ｂｂ抗体およびｐｄ－１タンパク質またはその断片を含む二重特異的エピトープ結合タンパク質およびその用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12331116B2 (https=) |
| EP (1) | EP4274852A4 (https=) |
| JP (1) | JP2024502371A (https=) |
| KR (2) | KR102618718B1 (https=) |
| CN (1) | CN117321079A (https=) |
| WO (1) | WO2022149050A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116615442A (zh) * | 2020-09-08 | 2023-08-18 | 优特力克斯有限公司 | 程序性细胞死亡1多肽变体 |
| USD1094401S1 (en) * | 2023-02-20 | 2025-09-23 | Sony Interactive Entertainment Inc. | Display screen or portion thereof with transitional graphical user interface |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102178323B1 (ko) * | 2013-11-29 | 2020-11-13 | 삼성전자주식회사 | 항 c-Met/항 Ang2 이중 특이 항체 |
| US10899840B2 (en) * | 2014-02-04 | 2021-01-26 | Pfizer Inc. | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| KR102259232B1 (ko) * | 2014-08-25 | 2021-05-31 | 삼성전자주식회사 | 항 c-Met/항 Ang2 이중 특이 항체 |
| HUE068868T2 (hu) * | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| JP2018537076A (ja) * | 2015-10-23 | 2018-12-20 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | プログラム可能な普遍的細胞受容体およびその使用法 |
| WO2017123548A1 (en) * | 2016-01-14 | 2017-07-20 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment |
| EP3433269B1 (en) * | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| WO2018127473A1 (en) * | 2017-01-03 | 2018-07-12 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| CN112210010B (zh) * | 2017-01-06 | 2023-12-05 | 优特力克斯有限公司 | 抗-人4-1bb抗体及其应用 |
| JP2020522495A (ja) * | 2017-05-30 | 2020-07-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| WO2019089753A2 (en) * | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| US20210054089A1 (en) * | 2018-03-23 | 2021-02-25 | Eli Lilly And Company | Anti-cd137 antibodies for combination with anti-pd-1 antibodies |
| WO2019241758A1 (en) * | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| JP7090204B2 (ja) * | 2018-07-19 | 2022-06-23 | イーライ リリー アンド カンパニー | 免疫チェックポイントを標的とする二重特異性抗体 |
| JP2022512541A (ja) * | 2018-08-29 | 2022-02-07 | シャタック ラボ，インコーポレイテッド | Ｐｄ－１系キメラタンパク質を含む併用療法 |
| JP2021535761A (ja) * | 2018-09-14 | 2021-12-23 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ｓＰＤ−１バリアント−Ｆｃ融合タンパク質 |
| WO2020068500A1 (en) * | 2018-09-26 | 2020-04-02 | Albert Einstein College Of Medicine | Mutant variants of pd-1 receptor with selective binding to pd-l1 and uses thereof |
| GB201817822D0 (en) * | 2018-10-31 | 2018-12-19 | Autolus Ltd | Binding domain |
| CN113286825B (zh) * | 2018-11-30 | 2024-06-18 | 爱必乐生物公司 | 抗pd-l1/抗4-1bb双特异性抗体及其用途 |
| WO2020229844A1 (en) * | 2019-05-15 | 2020-11-19 | Crescendo Biologics Limited | Binding molecules |
| US20210107969A1 (en) * | 2019-07-09 | 2021-04-15 | The Johns Hopkins University | Molecules, compositions and methods for treatment of cancer |
| CN110669137B (zh) * | 2019-10-24 | 2021-07-16 | 高新 | 一种多特异性抗体及其制备方法和用途 |
| CN116615442A (zh) * | 2020-09-08 | 2023-08-18 | 优特力克斯有限公司 | 程序性细胞死亡1多肽变体 |
-
2022
- 2022-01-11 KR KR1020227040417A patent/KR102618718B1/ko active Active
- 2022-01-11 US US17/647,665 patent/US12331116B2/en active Active
- 2022-01-11 KR KR1020237005801A patent/KR102576861B1/ko active Active
- 2022-01-11 JP JP2023541864A patent/JP2024502371A/ja active Pending
- 2022-01-11 EP EP22736677.0A patent/EP4274852A4/en active Pending
- 2022-01-11 CN CN202280009724.5A patent/CN117321079A/zh active Pending
- 2022-01-11 WO PCT/IB2022/000009 patent/WO2022149050A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022064924A5 (https=) | ||
| JP2024502371A5 (https=) | ||
| JP2022065174A5 (https=) | ||
| JP2021035388A5 (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| Zuo et al. | An efficient route to the production of an IgG-like bispecific antibody | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2020114210A5 (https=) | ||
| Fernández | Prokaryotic expression of antibodies and affibodies | |
| RU2015122484A (ru) | Агенты для лечения экспрессирующих клаудин раковых заболеваний | |
| CN105194661A (zh) | 时空可调性抑制病理性靶细胞的系统 | |
| JP2020195399A5 (https=) | ||
| JP2014113150A5 (https=) | ||
| JP2023539501A5 (https=) | ||
| HRP20140258T1 (hr) | Bispecifiäśni proteini koji se vežu na antigene | |
| JP2017503480A5 (https=) | ||
| JP2022009816A5 (https=) | ||
| WO2003046560B1 (en) | Self-assembly molecules | |
| JP2021525537A5 (https=) | ||
| Albrecht et al. | Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility | |
| JP2024507540A5 (https=) | ||
| JP2003517300A5 (https=) | ||
| JP2024527020A5 (https=) | ||
| JP2025503731A5 (https=) | ||
| Chinery et al. | Expression and purification of a trefoil peptide motif in a β‐galactosidase fusion protein and its use to search for trefoil‐binding sites | |
| CN114522244B (zh) | 视黄酸修饰的lytac分子及其制备方法和应用 |